KPV

What Is KPV?

KPV is a naturally occurring tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment (amino acids 11-13) of alpha-melanocyte stimulating hormone (α-MSH). Despite being only three amino acids long, KPV retains the anti-inflammatory activity of the full α-MSH molecule while lacking its melanogenic (skin-darkening) and appetite-modulating effects.

KPV exerts its anti-inflammatory effects by entering cells and directly inhibiting NF-κB — the master transcription factor controlling inflammatory gene expression. It can cross cell membranes due to its small size and enters the nucleus where it interacts with NF-κB p65 subunit, preventing inflammatory cytokine production.

The primary clinical interest in KPV centers on inflammatory bowel disease (IBD) and inflammatory skin conditions. Its small size enables oral delivery for gut inflammation and topical application for skin conditions, avoiding the need for injection.

What The Research Says

Animal studies in colitis models show KPV significantly reduces intestinal inflammation, decreases pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and accelerates mucosal healing. Oral KPV delivered in nanoparticle formulations showed enhanced efficacy in IBD models. KPV-loaded hydrogels demonstrated effectiveness in wound healing models.

In vitro studies confirm direct NF-κB inhibition without requiring melanocortin receptor activation — distinguishing KPV's mechanism from full-length α-MSH. This receptor-independent mechanism explains its anti-inflammatory effects without melanocortin side effects like skin darkening.

📚 Key Reference: PMID: 18721002 (KPV anti-inflammatory), PMID: 26145235 (colitis model)

Common Uses

• Inflammatory bowel disease (research)
• Gut inflammation and leaky gut (research)
• Inflammatory skin conditions (research)
• Wound healing (research)
• General anti-inflammatory protocols

Important Safety Information

As a fragment of an endogenous hormone, KPV has a favorable theoretical safety profile. Preclinical data shows no significant toxicity. The tripeptide is too small to be immunogenic. No melanocortin-related side effects (no skin darkening, no appetite changes). Limited human clinical data. Consult your provider.

Questions To Ask Your Provider

1. What inflammatory condition is KPV targeting?
2. What route of administration is being used and why?
3. How does KPV compare to conventional anti-inflammatories?
4. What markers of inflammation will be monitored?

Regulatory Status

NOT FDA-approved. Research use only. Available through some compounding pharmacies. No human clinical trials completed.